tbuckley/cabot-search huggingface dataset:
Adolescent health and Healthy China 2030: a cross-sectional study
Authors: Bin Dong, Zhiyong Zou, Yi Song, Peijing Hu, Dongmei Luo, Bo Wen, Di Gao, Xijie Wang, Zhaogeng Yang, Yinghua Ma, Jun Ma, Xiaobo Tian, Xiaona Huang, George C Patton
Journal: The Lancet (2018)
P1.01-19 Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases
Authors: R. Flippot, E. Auclin, P. Biondani, E. Le Rhun, J. Adam, D. Planchard, C. Caramella, C. Le Pechoux, L. Lacroix, A. Gazzah, L. Mezquita, B. Besse
Journal: Journal of Thoracic Oncology (2018)
Effect of a Low vs Intermediate Tidal Volume Strategy on Ventilator-Free Days in Intensive Care Unit Patients Without ARDS
Authors: Fabienne D. Simonis, Ary Serpa Neto, Jan M. Binnekade, Annemarije Braber, Karina C. M. Bruin, Rogier M. Determann, Geert-Jan Goekoop, Jeroen Heidt, Janneke Horn, Gerard Innemee, Evert de Jonge, Nicole P. Juffermans, Peter E. Spronk, Lotte M. Steuten, Pieter Roel Tuinman, Rob B.P. de Wilde, Marijn Vriends, Marcelo Gama de Abreu, Paolo Pelosi, Marcus J. Schultz
Journal: JAMA (2018)

It remains uncertain whether invasive ventilation should use low tidal volumes in critically ill patients without acute respiratory distress syndrome (ARDS).To determine whether a low tidal volume ventilation strategy is more effective than an intermediate tidal volume strategy.A randomized clinical trial, conducted from September 1, 2014, through August 20, 2017, including patients without ARDS expected to not be extubated within 24 hours after start of ventilation from 6 intensive care units in the Netherlands.Invasive ventilation using low tidal volumes (n = 477) or intermediate tidal volumes (n = 484).The primary outcome was the number of ventilator-free days and alive at day 28. Secondary outcomes included length of ICU and hospital stay; ICU, hospital, and 28- and 90-day mortality; and development of ARDS, pneumonia, severe atelectasis, or pneumothorax.In total, 961 patients (65% male), with a median age of 68 years (interquartile range [IQR], 59-76), were enrolled. At day 28, 475 patients in the low tidal volume group had a median of 21 ventilator-free days (IQR, 0-26), and 480 patients in the intermediate tidal volume group had a median of 21 ventilator-free days (IQR, 0-26) (mean difference, -0.27 [95% CI, -1.74 to 1.19]; P = .71). There was no significant difference in ICU (median, 6 vs 6 days; 0.39 [-1.09 to 1.89]; P = .58) and hospital (median, 14 vs 15 days; -0.60 [-3.52 to 2.31]; P = .68) length of stay or 28-day (34.9% vs 32.1%; hazard ratio [HR], 1.12 [0.90 to 1.40]; P = .30) and 90-day (39.1% vs 37.8%; HR, 1.07 [0.87 to 1.31]; P = .54) mortality. There was no significant difference in the percentage of patients developing the following adverse events: ARDS (3.8% vs 5.0%; risk ratio [RR], 0.86 [0.59 to 1.24]; P = .38), pneumonia (4.2% vs 3.7%; RR, 1.07 [0.78 to 1.47]; P = .67), severe atelectasis (11.4% vs 11.2%; RR, 1.00 [0.81 to 1.23]; P = .94), and pneumothorax (1.8% vs 1.3%; RR, 1.16 [0.73 to 1.84]; P = .55).In patients in the ICU without ARDS who were expected not to be extubated within 24 hours of randomization, a low tidal volume strategy did not result in a greater number of ventilator-free days than an intermediate tidal volume strategy.ClinicalTrials.gov Identifier: NCT02153294.
Impact of adding ramucirumab to paclitaxel in patients with advanced gastric cancer according to the level of ascites: A multicenter retrospective study
Authors: T. Masuishi, S. Kadowaki, H. Hirano, S. Kawai, T. Yamada, T. Moriwaki, N. Machida, N. Boku, K. Muro
Journal: Annals of Oncology (2018)
Role of AR-V7 and AR-FL in resistance to hormonal therapy in mCRPC: Independent actors or reciprocal drivers? A translational study by Meet-Uro group
Authors: M. Del Re, S. Crucitta, A. Sbrana, E. Rofi, F. Paolieri, L. Galli, A. Falcone, R. van Schaik, G. Jenster, R. Morganti, S. Pignata, R. Danesi
Journal: Annals of Oncology (2018)
P3.11-21 The Development of a Robust Radiology Quality Assurance (QA) Program in a Provincial High-Risk Lung Cancer Screening Pilot (HRLCSP)
Authors: M. Ang, H. Schmidt, R. Mani, G. Darling, D. Langer, P. Jain, V. Treister, M. Tammemagi, S. Flora
Journal: Journal of Thoracic Oncology (2018)
MA03.03 Prolonged Low-Dose Computed Tomography (LDCT) Screening Beyond 5 Years Reduces Overall and Lung Cancer Specific Mortality
Authors: U. Pastorino, F. Sabia, S. Sestini, M. Silva, M. Boeri, A. Cantarutti, N. Sverzellati, G. Sozzi, G. Corrao, A. Marchianò
Journal: Journal of Thoracic Oncology (2018)
P2.06-40 VISTA is Highly Expressed in Malignant Pleural Mesothelioma (MPM) and Independent of PD-L1 Expression
Authors: M. Zauderer, S. Muller, W. Lai, A. Ni, A. Jungbluth, M. Ginsberg, R. Daly, M. Hellmann, M. Ladanyi, J. Sauter
Journal: Journal of Thoracic Oncology (2018)
Tolerance and efficacy of immune-checkpoint inhibitors for cancer in people living with HIV (PWHIV)
Authors: A. Gobert, M. Veyri, A. Lavolé, H. Montaudié, N. Cloarec, L. Doucet, V. Gounant, M.-A. Massiani, C. Helissey, S. Bregigeon, C. Chouaid, C.-H. Poulet, M. Dewolf, M. Kerjouan, S. Beaucaire-Danel, S. Brosseau, G. Le Garff, V. Garrait, A.-G. Marcelin, J.-P. Spano
Journal: Annals of Oncology (2018)
Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase I clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer
Authors: A. Oaknin, S.L. Ellard, C. Leath III, V. Moreno, R. Kristeleit, W. Guo, S. Lu, D. Jenkins, K. McEachern, K. Yu Jen, S. Dunlap, E. Im, L. Gilbert
Journal: Annals of Oncology (2018)
P2.13-31 p.(Leu747Pro) Mutation Leads to Misdiagnosis in EGFR Mutation Assessment – Analysis in a Cohort of 1841 Polish NSCLC Patients
Authors: K. Duk, P. Skrońska, M. Skroński, A. Zdral, D. Kowalski, P. Rudzinski, R. Langfort, T. Orłowski, J. Chorostowska-Wynimko
Journal: Journal of Thoracic Oncology (2018)
Are socioeconomic position and region of residence barriers for referral to phase I trials?
Authors: K.T. Gad, S.O. Dalton, A.K. Duun-Henriksen, A. Krøyer, C. Johansen, M. Mau-Sorensen, U.N. Lassen
Journal: Annals of Oncology (2018)

Background: Referral pattern to phase 1 oncology trials is a highly relevant topic as the rapid development of new anticancer agents requires increased recruitment to early clinical trials. In this study, we investigated possible recruitment bias. The objective was to compare the socioeconomic position (SEP) and region of residence of patients referred to the Phase 1 Unit at Copenhagen University Hospital to a matched control group. Moreover, we investigated the influence of SEP on the inclusion in trials. Methods: Data from the Danish registries were compiled based on the civil registration number of patients referred to the Phase I Unit from 2005 to 2016. The association between SEP and referral was examined in a conditional logistic regression analysis based on referred patients and a matched control group. We adjusted for number of cancers, M-stage, comorbidity and psychological disturbances. The association between SEP and enrolment once referred was examined in a Cox regression analysis. Results: 1255 patients were referred. 1143 of these patients were eligible for this study. Complete data for analyses were available for 1026 patients and 229,788 controls matched on age, gender, type of cancer, year of diagnosis and time from diagnosis to referral. As barriers for referral, we identified short education as compared to long (OR 0.57, 95% CI 0.47-0.69), being outside workforce as compared to being within (OR 0.67, 95% CI 0.56-0.80), living alone as compared to living with a partner (OR 0.85, 95% CI 0.74-0.99) and living far from the Phase 1 Unit 0.34 as compared to living close to (95% CI 0.29-0.40). 252 patients enrolled in trials. Once referred, the socioeconomic parameters did not affect enrolment. Conclusions: In this single-center study, patients' SEP and region of residence affected referral pattern to phase 1 trials. This suggests inequality in the access to phase 1 trials. Legal entity responsible for the study: Danish Cancer Society Research Center, Copenhagen, Denmark. Funding: A.P. Møller Foundation, Knæk Cancer funds, The Health Foundation. Disclosure: All authors have declared no conflicts of interest.
P1.05-11 Role of EBUS-TBNA in Evaluation of Mediastinal Lymphadenopathy and Masses in Patients with Known or Suspected Extra-Pulmonary Malignancies
Authors: A. Nambirajan, M. Longchar, S. Mallick, A. Kakkar, K. Madan, S. Mathur, D. Jain
Journal: Journal of Thoracic Oncology (2018)
P2.06-29 Expression of Estrogen Receptor Beta (ERb) and its Prognostic Value in the Pleural Mesothelioma.
Authors: J. Rodriguez-Cid, O. García Acevedo, D. Bonilla-Molina, J.A. Alatorre Alexander, L. Martínez Barrera, J. Benjamín Contreras, E.S. Peña Mirabal
Journal: Journal of Thoracic Oncology (2018)
Abstract 12929: Longitudinal Strain Distribution is a Powerful Predictor for Functional Recovery in Patients With Tachycardia-induced Cardiomyopathy
Authors: Kenya Kusunose, Hirotsugu Yamada, Yoshihito Saijo, Hiromitsu Seno, Yukina Hirata, Yuta Torii, Susumu Nishio, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki, Masataka Sata
Journal: Circulation (2016)

Introduction: Tachycardia-induced cardiomyopathy (TIC) is a potentially reversible cardiomyopathy by effective treatment of the tachyarrhythmia. However, cases without improvement of left ventricular (LV) systolic function were found occasionally. The diagnosis of TIC can be challenging, and the role of echocardiographic imaging in the prediction of LV functional recovery is limited. Hypothesis: We hypothesized that echocardiographic imaging might provide additional information to predict LV functional recovery in patients with tachyarrhythmia. The aim of this study was to assess the time course of LV functional recovery in presumptive TIC and the predictors of the recovery in such patients. Methods: We prospectively performed LV segmental longitudinal strains (LS) by 2-dimensional speckle tracking in 71 consecutive patients (65±16 years; 61% men) with tachyarrhythmia and reduced LV ejection fraction (EF) without any other known cardiovascular disease. Relative apical LS ratio (RALSR) was defined as a marker of strain distribution using following equation: average apical LS / (average basal LS + average mid LS). Results: Improvement in EF within 6 months after treatment of index arrhythmia was observed in 41 patients, and the EF did not improve in 30 patients. In univariate analysis, lower EF at baseline (hazard ratio: HR: 0.59 per 1SD, p=0.04) and higher RALSR (HR: 11.2 per 1SD, p &lt;0.001) were associated with no recovery in the EF during follow-up. After adjustment for clinical variables, the significant predictor of LV systolic functional recovery was RALSR (HR: 22.1 per 1SD, p=0.001). A RALSR of 0.61 was sensitive (71%) and specific (90%) in differentiating LV systolic functional recovery (area under the curve: 0.88). Conclusions: The RALSR was associated with LV systolic functional recovery. This information might be useful for clinical evaluation and follow-up in patients with reduced EF.
Updated meta-analysis of randomized controlled trials (RCTs) to determine the CDK 4/6 inhibitors associated venous thromboembolism (VTE) risk in hormone receptor-positive breast cancer (BC) patients
Authors: K.Z. Thein, S. Ball, M.H. Zaw, A.M. Tun, M. Quirch, F. Hardwicke, N. D'Cunha, L. Tijani, C. Jones, T.H. Oo
Journal: Annals of Oncology (2018)
Abstract 13896: Combined Therapy With SS31 and Mitochondria Markedly Attenuates Myocardial Ischemia-Reperfusion Injury in Rat
Authors: Hon-Kan Yip, Pei-Lin Shao
Journal: Circulation (2017)

Introduction: This study tested the hypothesis that combined SS31-mitochondria therapy was better than either one on protecting rat myocardial ischemia-reperfusion (IR) injury (i.e., 30-min ischemia/72h reperfusion followed by euthanizing animals) Methods: Adult-male-SD rats (n=8/each group) were randomized into group 1 (sham-operated control), group 2 (IR), group 3 [IR-SS31 (2 mg intra-peritoneal injection at 30min/24h/48h after IR)], group 4 [IR-mitochondria (2000 μg)/derived from donor liver by intra-venous administration/30 min after IR procedure), and group 5 (IR-SS31-mitochondria). Results: In-vitro study showed menadione (25μM)-induced protein upregulations of oxidative-stress (NOX-1/NOX-2/NOX4/oxidized protein) in H9C2 cells were progressively suppressed by stepwise-increased SS31 doses (5μM/25μM /50μM), whereas protein expression of SIRT1/SIRT3 and ATP level showed an opposite pattern to oxidative-stress (all p<0.0001). By 72h after IR, the left-ventricular-ejection-fraction (LVEF) was highest in...
Use of nuclear-localized androgen receptor splice variant 7 protein in CTCs after 1st androgen receptor signaling inhibitor (ARSi) as a predictive biomarker for overall survival on a second ARSi or taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC)
Authors: H.I. Scher, R.P. Graf, M. Hulling, E. Carbone, R. Dittamore
Journal: Annals of Oncology (2018)
MA18.02 The Impact of Treatment Evolution in NSCLC (iTEN) Model: Development and Validation
Authors: D. Moldaver, M. Hurry, D. Tran, W. Evans, P. Cheema, R. Sangha, R. Burkes, B. Melosky, E. Orava, D. Grima
Journal: Journal of Thoracic Oncology (2018)
P3.04-23 Phase 1b/2 Study to Evaluate Novel Combinations With Oleclumab (MEDI9447) in Previously Treated Advanced EGFRm NSCLC
Authors: N. Rizvi, C. Shu, S. Goldberg, V. Papadimitrakopoulou, D.R. Camidge, S. Patel, K. Marrone, S. Kim, D. Kim, H. Hsieh, N. Mueller, R. Kumar, J. Englert, K. Park
Journal: Journal of Thoracic Oncology (2018)
MA06.06 An Ex-Vivo Patient-Derived, Immunocompetent (PDI) Culture System to Evaluate Immunotherapeutic Agents’ Anti-Tumor Efficacy
Authors: Z. Tano, S. Kiesgen, N. Chintala, J. Dozier, J. Messinger, K.S. Tan, P. Adusumilli
Journal: Journal of Thoracic Oncology (2018)
Gene expression profile (GEP) and survival among patients with advanced ovarian cancer
Authors: E. Høgdall, C.K. Høgdall, P.-T. Vo, W. Zhou, L. Huang, M. Marton, S.M. Keefe, M. Busch-Sørensen, S.M. Sørensen, J. Georgsen, E. Mejlgaard, L. Nedergaard, T. Steiniche
Journal: Annals of Oncology (2018)
Efficacy and safety of telotristat ethyl (TE) in combination with lanreotide (LAN) in patients with a neuroendocrine tumour and carcinoid syndrome (CS) diarrhoea (CSD): Meta-analysis of phase III double-blind placebo (PBO)-controlled TELESTAR and TELECAST studies
Authors: D. Hörsch, R. Garcia-Carbonero, J.W. Valle, P. Perros, S. Welin, L. Keeber, A. Houchard, P. Lapuerta
Journal: Annals of Oncology (2018)
P2.15-09 The Impact of Treatment Evolution in NSCLC (iTEN) Model: Survival and Cost of Treating Patients with Advanced NSCLC in 2017
Authors: D. Moldaver, M. Hurry, D. Tran, W. Evans, P. Cheema, R. Sangha, R. Burkes, B. Melosky, E. Orava, D. Grima
Journal: Journal of Thoracic Oncology (2018)
P1.03-08 Detection of PTCH1 Gene Variants in Non-Small Cell Lung Cancer Patients from China
Authors: T. Xu, C. Xu, W. Wang, Q. Zhang, W. Zhuang, Y. Zhu, Z. Huang, Y. Chen, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2018)
P2.13-06 TP53 Status in Relation to Response to Anti-ALK Agents in Patients with EML4-ALK-Translocated NSCLC
Authors: M. Canale, A. Delmonte, C. Dazzi, A. Gamboni, M. Puccetti, S. Bravaccini, C. Casanova, M. Papi, M. Mariotti, N. De Luigi, G. Minuti, D. Calistri, M. Bonafè, L. Crinò, P. Ulivi
Journal: Journal of Thoracic Oncology (2018)
Ecological Validity in Bilingualism Research and the Bilingual Advantage
Authors: Esti Blanco-Elorrieta, Liina Pylkkänen
Journal: Trends in Cognitive Sciences (2018)

Traditional research in bilingualism has consistently found that switching languages is effortful, placing demands on neural systems of cognitive control. This finding runs counter to most bilinguals' intuitive experience. We review a body of recent work showing that, in fact, when bilinguals switch languages voluntarily, both the behavioral cost of switching and the associated recruitment of cognitive control areas are greatly reduced or completely eliminated. This suggests that switching languages is not inherently effortful, but rather, particular communicative demands may make it costly. The new evidence also challenges the basic premise underlying the bilingual advantage hypothesis. We articulate a more nuanced version of it, in which the advantage is limited to bilinguals who frequently switch languages based on external constraints.
Prognostic value of MRI-derived residual retropharyngeal lymph node after intensity-modulated radiotherapy in nasopharyngeal carcinoma and a nomogram for the prediction of it
Authors: W.-Z. Li, H. Liang, X. Lv, L.-R. Ke, Y.-F. Ye, Y.-H. Yu, W.-Z. Qiu, G.-Y. Liu, X.-J. Huang, K.-Y. Liu, S.-H. Lv, X. Guo, Y.-Q. Xiang, W.-X. Xia
Journal: Annals of Oncology (2018)
P1.16-57 Outcomes of Pulmonary Resection in Elderly Non-Small Cell Lung Cancer Patient
Authors: A. Tantraworasin, S. Siwachat, N. Tanatip, N. Lertprasertsuke, S. Kongkarnka, J. Euathrongchit, Y. Wannasopha, T. Suksombooncharoen, B. Chewaskulyong, E. Taioli, S. Saeteng
Journal: Journal of Thoracic Oncology (2018)
High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen
Authors: Norbert Ndjeka, Kathryn Schnippel, Iqbal Master, Graeme Meintjes, Gary Maartens, Rodolfo Romero, Xavier Padanilam, Martin Enwerem, Sunitha Chotoo, Nalini Singh, Jennifer Hughes, Ebrahim Variava, Hannetjie Ferreira, Julian te Riele, Nazir Ismail, Erika Mohr, Nonkqubela Bantubani, Francesca Conradie
Journal: European Respiratory Journal (2018)

South African patients with rifampicin-resistant tuberculosis (TB) and resistance to fluoroquinolones and/or injectable drugs (extensively drug-resistant (XDR) and preXDR-TB) were granted access to bedaquiline through a clinical access programme with strict inclusion and exclusion criteria. PreXDR-TB and XDR-TB patients were treated with 24 weeks of bedaquiline within an optimised, individualised background regimen that could include levofloxacin, linezolid and clofazimine as needed. 200 patients were enrolled: 87 (43.9%) had XDR-TB, 99 (49.3%) were female and the median age was 34 years (interquartile range (IQR) 27–42). 134 (67.0%) were living with HIV; the median CD4 + count was 281 cells·μL −1 (IQR 130–467) and all were on antiretroviral therapy. 16 out of 200 patients (8.0%) did not complete 6 months of bedaquiline: eight were lost to follow-up, six died, one stopped owing to side effects and one was diagnosed with drug-sensitive TB. 146 out of 200 patients (73.0%) had favourable outcomes: 139 (69.5%) were cured and seven (3.5%) completed treatment. 25 patients (12.5%) died, 20 (10.0%) were lost from treatment and nine (4.5%) had treatment failure. 22 adverse events were attributed to bedaquiline, including a QT interval corrected using the Fridericia formula (QTcF) &gt;500 ms (n=5), QTcF increase &gt;50 ms from baseline (n=11) and paroxysmal atrial flutter (n=1). Bedaquiline added to an optimised background regimen was associated with a high rate of successful treatment outcomes for this preXDR-TB and XDR-TB cohort.
A multi-omic analysis for prospective patient stratification in localised colorectal cancer (CRC)
Authors: N. Tarazona Llavero, E. Fontana, V. Gambardella, F. Gimeno-Valiente, J. Castillo, A. Calon, C. Martínez-Ciarpaglini, L. Peiró-Chova, M. Huerta, S. Zuñiga, P. Rentero-Garrido, J. Montón-Bueno, D. Roda, S. Roselló, B. Bellosillo, A. Vivancos, G. Nyamundana, C. Montagut, A. Sadanandam, A. Cervantes
Journal: Annals of Oncology (2018)
Efficacy and safety for apatinib combined with oxaliplatin and S1 in initially treated metastatic gastric cancer: A single-center observational study
Authors: J. Peng, L. Peng, H. Wu, K. Wu, W. Chen, C. Xie, J. Xu, X. Zhang, D. Chen, S. Cai, Y. He
Journal: Annals of Oncology (2018)
Relation of overall survival, progression free survival, post progression survival and response rate in four randomized Japanese phase III trials comparing various combinations of S-1 therapy for first-line treatment of advanced gastric cancer
Authors: M. Takeuchi, W. Ichikawa, K. Shitara, Y. Sunakawa, K. Oba, W. Koizumi, Y. Sakata, H. Furukawa, M. Takeuchi, M. Fujii
Journal: Annals of Oncology (2018)
The prognostic role of morphology and Ki67 in grade 3 gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN)
Authors: A.R. Hayes, M. Furnace, C. Rundell, R. Shah, G. Muller, C. Thirlwell, T.V. Luong, C. Toumpanakis, M. Caplin, D. Mandair
Journal: Annals of Oncology (2018)
P2.04-26 Interim Results from a Phase I/II Trial of Nivolumab in Combination with CIMAvax-EGF as Second-Line Therapy in Advanced NSCLC
Authors: G. Dy, A. Dozier, M. Reid, K. Lee, A. Miller, P. Wallace, I. Puzanov, M. Opyrchal, M. Ernstoff, C. Johnson, Z. Mazorra, D. Saavedra, K. Leon, A. Lage, T. Crombet
Journal: Journal of Thoracic Oncology (2018)
Distinct Clinicopathologic Characteristics and Prognosis Based on the Presence of Ground Glass Opacity Component in Clinical Stage IA Lung Adenocarcinoma
Authors: Aritoshi Hattori, Shunki Hirayama, Takeshi Matsunaga, Takuo Hayashi, Kazuya Takamochi, Shiaki Oh, Kenji Suzuki
Journal: Journal of Thoracic Oncology (2018)
P2.11-10 Potential Utility of a Positive EarlyCDT®-Lung Blood Biomarker Test in Indeterminate Pulmonary Nodules
Authors: J. Jett, G. Healey, A. Murray, G. Hamilton-Fairley, S. Fraser, L. Peek, P. Mazzone, P. Massion
Journal: Journal of Thoracic Oncology (2018)
P2.09-22 Relevance of Results of Intraoperative Pleural Lavage Cytology and Histological Subtype in Lung Adenocarcinoma
Authors: M. Mikubo, R. Maruyama, K. Matsushima, S. Hayashi, M. Naito, Y. Matsui, K. Shiomi, M. Ichinoe, T. Yoshida, K. Satoh
Journal: Journal of Thoracic Oncology (2018)
P1.14-15 Prevalence of Mediastinal Tumors Using Low-Dose Spiral Computed Tomography in Healthy Population
Authors: I. Kasuga, H. Maezawa, S. Gamo, Y. Yokoe, Y. Yanagihara, H. Yoshino, Y. Sato, E. Imazeki, Y. Sakano, D. Takahashi, M. Sato, K. Wakabayashi, O. Otsubo
Journal: Journal of Thoracic Oncology (2018)
Outcome following unplanned excision in soft tissue sarcoma: Results of a multicentre study including 728 patients
Authors: M.A. Smolle, P.-U. Tunn, E. Goldenitsch, F. Posch, J. Szkandera, M. Bergovec, B. Liegl-Atzwanger, A. Leithner
Journal: Annals of Oncology (2018)